James L. Herman | Vice President of National Accounts  and Chief Compliance Officer Cumberland Pharmaceuticals “Our gastroenterology products have been a significant driver of growth for  the Company. With the addition of Omeclamox-Pak and the repositioning of  Kristalose, we are creating increased demand while while maximizing the  use of our internal resources. We see a bright future for both brands.”  As the only prescription laxative available in a  powder formulation, Kristalose ®  (lactulose) for Oral  Solution provides patients with distinct benefits.  A unique, dry powder crystalline formulation  of lactulose used to treat chronic and acute  constipation, Kristalose is the only prescription  laxative available in pre-measured powder packets,  making it easily portable. Kristalose dissolves  quickly in four ounces of water, offering patients a  virtually taste-free, grit-free and essentially calorie- free alternative to lactulose syrups. A preference  trial shows 77 percent of patients surveyed prefer  the taste, consistency and portability of Kristalose  over similar products in syrup forms.  Since acquiring exclusive U.S. commercial rights to  Kristalose in 2006, Cumberland has marketed the  product to gastroenterologists, internists and other  high prescribers of laxatives. Using the preference  data as a cornerstone of our marketing efforts,  we have made significant gains following our  repositioning of the brand in early 2014. The new  marketing strategy includes an enhanced coupon  program for the product, which allows us to provide  additional support to patients. As a result of these  efforts, Kristalose now ranks as the Company’s top  selling product. Omeclamox ® -Pak is a branded prescription  product that combines three well-known and  widely prescribed medications for the treatment of  Helicobacter pylori (H. pylori) infection and related  duodenal ulcer disease. Packaged together for  patient convenience, Omeclamox-Pak combines  omeprazole, amoxicillin and clarithromycin in a  simple-to-follow 10-day course of therapy that  has been shown to eradicate H. pylori in up to 90  percent of patients. It is the first FDA-approved triple therapy  combination medication to contain omeprazole  as the proton pump inhibitor, which works to  decrease the amount of acid the stomach produces.  Amoxicillin and clarithromycin are both antibiotic  agents, which allow the stomach to heal by  hindering the growth of H. pylori.  After acquiring rights to the brand through an  agreement with Pernix Therapeutics in October  2013, Cumberland’s field sales force began  promoting the product to the gastroenterology  market alongside Kristalose in January 2014.  Under the terms of the agreement, Cumberland  is responsible for the product’s U.S. marketing  and distribution, as well as promotion to  gastroenterologists, while Pernix promotes the  product to select primary care and other physicians.  In the year since its launch, Omeclamox-Pak has  proven to be an excellent strategic fit as evidenced  by a significant increase in prescriptions among our  target physicians. 7 Omeclamox ® -Pak Kristalose ®